RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Perspective: Issues with Proposed Regulatory Pathways for Follow-on Biologics

Perspective: Issues with Proposed Regulatory Pathways for Follow-on Biologics

Posted 01 August 2011 | By Alok Byopadhyay, PhD, RAC

Most small molecule drugs are produced through some chemical synthesis steps and purified through a rigorous process. This enables production of substantially pure active pharmaceutical ingredient (API), which is characterized further by various physical and chemical methods.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.